# Lin Shen

Source: https://onco.cc/people/shen-lin/  
OnCo record `shen-lin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.

## Summary

Lin Shen is Professor and Director of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital in Beijing. Her group ran the phase 1 and randomised phase 2 trials of satricabtagene autoleucel, the Claudin 18.2 CAR-T cell therapy from CARsgen Therapeutics also known as CT041, which produced the first CAR-T therapy approved for a solid tumour, in gastric cancer. Her publications include the interim phase 1 results of Claudin 18.2-specific CAR T cells in gastrointestinal cancers, which also included pancreatic cancer patients. She leads Chinese gastric cancer immunotherapy and HER2 studies, with interests in CAR-T for solid tumours and immunotherapy.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor and Director, Department of GI Oncology, Peking University Cancer Hospital
- Specialisms: Gastric cancer; Claudin 18.2; CAR-T for solid tumours; Immunotherapy

## Sources

- Peking University Cancer Hospital: https://www.bjcancer.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20L%5BAuthor%5D%20Peking%20University%20Cancer%20Hospital%20claudin18.2%20CAR-T

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- drugs: [Satricabtagene autoleucel](https://onco.cc/drugs/satricabtagene-autoleucel/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/)
- institutions: [Peking University Cancer Hospital](https://onco.cc/institutions/pku-cancer-hospital/)
- key papers: [BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer](https://onco.cc/key-papers/paper-breakwater-nejm-2025/), [CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma](https://onco.cc/key-papers/paper-checkmate-649-lancet-2021/), [Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial](https://onco.cc/key-papers/paper-ct041-st-01-lancet-2025/)
- trials: [CT041-ST-01](https://onco.cc/trials/nct04581473/)

---
JSON: https://onco.cc/api/v1/entities/shen-lin.json